Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Adial Pharmaceuticals Announces Planned Expansion of Lead Asset AD04 into Opioid Addiction Including Synthetic Opioids Such as Fentanyl

Adial Pharmaceuticals (ADIL) Bullish View Reiterated at Maxim Group Following Lead Asset Expansion

December 13, 2018 12:27 PM EST

Maxim Group analyst Jason McCarthy reiterated a Buy rating and $5 price target on Adial Pharmaceuticals Inc (NASDAQ: ADIL) after the company announced it is expanding its activities around its lead asset AD04, beyond alcohol use disorder (AUD) to now include potential use in patients with opioid use disorder (OUD).

The analyst... More

Adial Pharmaceuticals (ADIL) Halted on LUDP

December 13, 2018 10:55 AM EST

Adial Pharmaceuticals (NASDAQ: ADIL) Halted on LUDP

... More

Adial Pharmaceuticals (ADIL) Surges on Plans to Expand Lead Asset AD04 into Opioid Addiction

December 13, 2018 9:27 AM EST

Adial Pharmaceuticals (NASDAQ: ADIL) is gaining 37% in pre-open trade after the company... More